ProfileGDS5678 / 1428914_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 84% 82% 82% 83% 85% 82% 86% 86% 88% 87% 85% 85% 86% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.1744784
GSM967853U87-EV human glioblastoma xenograft - Control 25.9905882
GSM967854U87-EV human glioblastoma xenograft - Control 36.004482
GSM967855U87-EV human glioblastoma xenograft - Control 46.3137883
GSM967856U87-EV human glioblastoma xenograft - Control 56.3386385
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.8086382
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.3453186
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.5166686
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8493888
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.647187
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.4064685
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.4716585
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.5883986
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.6430287